Results We depict nine extremely rare variants (up to 1% incidence) (table 1) Reported incidence in literature: 0.5% sarcomatoid, rhabdomyosarcoma 9%, malignant melanoma less than 1%, neuroendocrine up to 2%, and large cell neuroendocrine is even rare (12% of all neuroendocrine) glassy cell 1%, carcinosarcoma about 70 cases reported till date. All cases are presented in advanced stages. (table 2). In spite of various multimodal chemotherapy regimens, we saw dismal outcomes. (OS range 3 -11 months).

Conclusion With conventional management prognosis of rare subtypes is dismal. Precision oncology is the road ahead for tailored treatment of aggressive histologies. Widespread establishment of rare cancer registries to meticulously record past present and future of each rare subtype is prudent.

Disclosures There is no conflict of interest between the authors of the article.